Journal of Clinical Oncology
Articles in this Issue
Efficacy profile of nanoliposomal irinotecan + fluorouracil and leucovorin (nal-IRI+5-FU/LV) in gemcitabine-refractory metastatic pancreatic adenocarcinoma in elderly North American patients: A real-word experience.
e16382 Background: Second-line treatment options for metastatic pancreatic adenocarcinoma (mPDAC) remain limited. The NAPO...
Spatial transcriptome to identify biomarkers for endocrine sensitivity of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC).
e12501 Background: Intratumor heterogeneity is associated with endocrine sensitivity in breast cancer. However, no relevan...
PDLIM2 expression and characteristics in KRAS- mutated lung adenocarcinoma.
e20561 Background: It has been shown that PDLIM2 is expressed at higher levels in normal lungs in comparison to cancerous...
Comparative study between neoadjuvant hormone therapy plus CDK-4/6 inhibitors versus neoadjuvant chemotherapy for hormone receptor–positive breast cancer patients.
e12667 Background: Neoadjuvant Chemotherapy (NACT) has traditionally been employed in patients with operable and locally a...
Real-world comparison of atezolizumab/bevacizumab vs durvalumab/tremelimumab in decompensated hepatocellular carcinoma.
e16159 Background: Pivotal trials established atezolizumab-bevacizumab and durvalumab-tremelimumab as first-line therapies...
Association of solid tumor patients’ characteristics and cure expectations with their portal-reported health-related values.
e24114 Background: Patient portals are an efficient, valid method of assessing patients’ health-related values (HRVs) to i...
DAREON-8: Updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC).
8089 Background: Obrixtamig (BI 764532) is a DLL3/CD3 IgG-like T-cell engager that has shown promising efficacy in ES-SCLC...
Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies (ACT-GI): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.
3580 Background: Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of chemotherapy. Persistent CIT (n...
Survival outcomes by insurance coverage in non-Hodgkin lymphoma (NHL): Experience from two academic centers and a safety-net health system.
e19058 Background: The impact of insurance coverage on survival in NHL has been described, but it remains unclear how this...
Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
8006 Background: Brain metastases (BM) are common in patients (pts) with SCLC and are associated with poor outcomes. Tarla...
Genomic characterization of <i>SMARCA4</i> -mutant versus wild-type non–small cell lung cancer in a Chinese population: A large-scale next-generation sequencing study.
8547 Background: SMARCA4 is a core component of the SWI/SNF chromatin remodeling complex and plays a critical role in tran...
Analysis of information received and perceived by patients with metastatic breast cancer: Results of the Croyances et Réalités 3 French survey.
1113 Background: Despite therapeutic advances, metastatic breast cancer (mBC) and its treatments substantially impact qual...
Immune checkpoint inhibitor (ICI) toxicity in a large prospective cohort of patients with solid tumors: The I-CHECKIT study (SWOG S2013).
2640 Background: Based on clinical trials, the expected rate of ≥ grade 3 iRAEs is ~15% for single agent ICIs and ~30-50%...
A novel peptide decoy DMp39 targeting mitochondrial metabolism to enhance chemotherapy response.
e20720 Background: Chemotherapy resistance remains a major clinical challenge, leading to treatment failure and disease re...
Real-world outcomes of enfortumab vedotin plus pembrolizumab compared with platinum-based chemotherapy in metastatic urothelial carcinoma in a propensity-matched global analysis.
e16597 Background: Enfortumab vedotin plus pembrolizumab has shown superior efficacy compared with platinum-based chemothe...
Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
7028 Background: Axi-cel, autologous anti-CD19 CAR T-cell therapy, showed long-term survival and curative potential in R/R...
Envafolimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial.
4118 Background: China bears a high biliary tract cancer (BTC) burden, with cholangiocarcinoma rising incidence ( > 6/1...
Novel isocryptolepine analogs with submicromolar antiproliferative activity: En route to next-in-class antiestrogens for the treatment of breast cancer.
e15166 Background: Estrogen receptor α (ERα)-positive breast cancer (BC) comprises ~70% of cases. Despite advances in endo...
Comprehensive molecular profiling in advanced non–small cell lung cancer (NSCLC): Measurable survival and value impacts of implementation.
11054 Background: Comprehensive molecular profiling (CMP) is key to precision oncology in advanced non–small cell lung can...
Final results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for high-risk non–muscle-invasive bladder cancer patients unresponsive to Bacillus Calmette-Guerin.
4599 Background: Radical cystectomy (RC) was the standard of care for high-risk non-muscle-invasive bladder cancer (HR NMI...
Impact of VT-EBV-N on disease-free survival as post-remission therapy in EBV-positive extranodal NK/T-cell lymphoma: A randomized, double-blind, placebo-controlled phase 2 study.
7005 Background: Extranodal NK/T-cell lymphoma (ENKL) is an aggressive EBV-associated malignancy. Although complete remiss...
Trends and racial disparities in pulmonary embolism–related mortality among older adults with neoplasms: A population-based retrospective study in the United States from 1999-2020.
11157 Background: Pulmonary embolism (PE) remains a major cause of preventable mortality, particularly among older adults...
Cabozantinib in high-grade neuroendocrine neoplasms.
4183 Background: High grade neuroendocrine neoplasms (HG-NENs) are treated with platinum doublets mirroring guidelines for...
Patient trust in oncologists versus artificial intelligence for cancer-related questions.
11105 Background: Artificial intelligence tools, including the recent introduction of ChatGPT Health, are increasingly acc...
TREGCHECK 102: A study of tagmokitug (CHS-114) in combination with toripalimab and/or other treatments in participants with advanced solid tumors.
TPS2689 Background: Advanced solid tumors frequently exhibit resistance to standard therapies, including immune checkpoint...